LIPO: Lipella Pharmaceuticals Inc. Stock

by  •  • Comments Off on LIPO: Lipella Pharmaceuticals Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3.31
Enterprise Value ($M) 1.96
Book Value ($M) 1.46
Book Value / Share 1.21
Price / Book 2.27
NCAV ($M) 1.38
NCAV / Share 1.14
Price / NCAV 2.40

Profitability (mra)
Return on Invested Capital (ROIC) -2.79
Return on Assets (ROA) -1.19
Return on Equity (ROE) -1.36

Liquidity (mrq)
Quick Ratio 2.97
Current Ratio 2.97

Balance Sheet (mrq) ($M)
Current Assets 2.08
Assets 2.16
Liabilities 0.70
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
6 days ago 13D/A Kaufman Jonathan H
6 days ago 13D/A Chancellor Michael B
01-03 13G/A Sabby Management, Llc
11-14 13G/A Huang Leaf 5.70 -87.50
11-14 13G/A Gruber Michele 3.90 -87.16

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 ☐ TRANSITION REP
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 ☐ TRANSITION REPORT P
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 ☐ TRANSITION REPORT
2024-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 3,615 20,597 17.55
2025-02-03 6,973 29,532 23.61
2025-01-31 11,882 21,670 54.83
2025-01-30 4,443 17,409 25.52

(click for more detail)

Similar Companies
LEXX – Lexaria Bioscience Corp. LFVN – LifeVantage Corporation
LGVN – Longeveron Inc. LIXT – Lixte Biotechnology Holdings, Inc.
LPCN – Lipocine Inc.


Financial data and stock pages provided by
Fintel.io